MedTrace Logo

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

NCT05509569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2025-11-17

No results posted yet for this study

Summary

This study is a survey in Japan of Icatibant subcutaneous injection 30 mg syringe used to treat children or teenagers with acute attacks of hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

The main aim of the study is to check for side effects related from Icatibant subcutaneous injection 30 mg syringe and to check if Icatibant subcutaneous injection 30 mg syringe improves acute attacks of HAE.

During the study, pediatric participants with HAE will take Icatibant subcutaneous injection 30mg syringe according to their clinic's standard practice. The study doctors will check for side effects from Icatibant subcutaneous injection 30 mg syringe for 3 months.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

DRUG

Icatibant

Icatibant, 10 to 30 mg, Subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-24
Primary Completion
2025-10-31
Completion
2025-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05509569 on ClinicalTrials.gov